MALVERN, PA — In a strategic move to strengthen its position as a leading provider of pharmaceutical market access and regulatory insight, HMP Global has announced a definitive agreement to acquire Drug Channels Institute (DCI). While the terms of the agreement have not been disclosed, the acquisition aligns with HMP Global’s commitment to deliver enhanced value to its expansive customer base.
DCI, established in 2012 by industry authority Adam J. Fein, Ph.D., is a trusted source of extensive market intelligence, providing data-driven insights, research, and analysis of the $1.5tn pharmaceutical landscape. DCI has become an essential resource for understanding the intricacies of pharmaceutical economics and the complex pharmacy distribution and reimbursement system.
The acquisition follows HMP Global’s recent purchase of Proximity Health, LLC – now known as HMP Market Access Insights – a Palo Alto-based company renowned for delivering actionable analysis and recognized as the ‘gold standard’ provider of value-based care and oncology market access research.
Jeff Hennessy, Chairman and CEO of HMP Global, expressed his anticipation for the acquisition. “Under Adam’s leadership, DCI has built an exceptional reputation as the leading provider of information and analysis in the pharmaceutical and broader healthcare sectors,” he said. “We look forward to welcoming Adam and the team to HMP Global and to making significant investments in DCI and this space to drive innovation.”
The integration of Drug Channels Institute and HMP Market Access Insights will form a new division within HMP Global. The merger promises expanded research capabilities, a wider range of services, in-person events, and a more comprehensive understanding of sector dynamics for clients.
Jeff Hennessy, Jr., HMP Global Chief Operating Officer and President of HMP Omnimedia, sees DCI as a perfect addition to their portfolio. “Together, we will be better positioned to help our clients navigate industry complexities and make more informed decisions,” he said.
As part of the integration into HMP Global, DCI leadership will remain in place. Dr. Fein will become President of Drug Channels Institute, and Paula Fein will assume the role of Vice President, Business Development.
Dr. Fein expressed enthusiasm for the new partnership with HMP Global. “We look forward to capitalizing on HMP’s investments in DCI so we can deliver new value for our customers and create new opportunities for collaboration,” he said.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.